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Introduction {#sec1}
============

Hematopoietic stem cells (HSCs) reside in the bone marrow (BM), where they receive survival and differentiation signals from several cell types, including endothelial and multiple lineages of peri-vascular mesenchymal cells ([@bib42]). Similarly, cancer growth and chemo-resistance have been hypothesized to be dependent on a malignant microenvironment that is highly vascularized ([@bib9], [@bib48]). This relationship is well illustrated in epithelial cancers, where increased angiogenesis supports growth and metastasis ([@bib50]).

Acute myeloid leukemia (AML) is an aggressive leukemia often accompanied by life-threatening cytopenias. The cure rate of AML is only 5%--15% in patients greater than 60 years old ([@bib8]). Thus, there is an unmet clinical need for more effective therapies, especially because the mainstay of treatment has not changed significantly in the last 30 years ([@bib8]). To develop more selective and better-tolerated therapies, it is critical that we understand how AML cells grow, outcompete healthy hematopoiesis, and eventually generate an environment supportive of chemo-resistant leukemia stem cells. Alterations in BM innervation and stroma have been described in late stages of disease ([@bib16]). However, the dynamic process leading to this stage is unknown, and its dissection promises to uncover new therapeutic targets. There are reports of vascular endothelial growth factor (VEGF) secretion by AML cells ([@bib11]) and of increased BM microvasculature density in patients ([@bib1], [@bib23], [@bib45]) and, more recently, murine models ([@bib16]) at advanced stages of disease. However, clinical trials investigating anti-angiogenic therapy in AML patients have been disappointing ([@bib12], [@bib44], [@bib62]). Thus, questions remain about the effect of AML growth on BM vasculature and whether vascular remodeling may be beneficial for the disease. We hypothesized that AML-induced BM vascular remodeling may be more complex than simple induction of angiogenesis and that progressive, nuanced changes could shape the ecological competition between leukemia and healthy hematopoiesis. A spatiotemporal understanding of these changes may point to novel candidate interventions that could restore BM normal ecology, including HSC function, and in turn make AML cells more susceptible to chemotherapy.

Here, we present a high-resolution, longitudinal analysis of the progressive and region-specific vasculature remodeling induced by AML, with a particular focus on the implications for healthy hematopoiesis. We uncovered (1) morphological and functional changes in surviving vessels, namely attempted but failed angiogenesis and increased transendothelial migration of hematopoietic cells; (2) specific loss of endosteal vessels, accompanied by loss of osteoblastic cells and, most importantly, HSCs; and (3) endosteal vasculature induction as a successful approach to rescue healthy HSCs and improve the efficacy of induction chemotherapy.

Results {#sec2}
=======

Intravital Microscopy Enables the Study of AML Cells, Healthy Hematopoietic Cells, and the BM Microenvironment Simultaneously {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------

To study the effects of AML growth on BM vasculature and HSCs as disease propagates through the tissue, we used the well-established MLL-AF9-driven murine model of AML, which recapitulates phenotypic and pathological features of human MLL-rearranged AML ([@bib33], [@bib56]). To generate leukemia cells detectable by intravital microscopy, we harvested myeloid progenitor cells from donor mice that expressed high levels of fluorescent proteins (FP), transduced them with a retroviral vector encoding the oncogene and GFP, and injected them into sub-lethally irradiated recipients. With this approach, we generated multiple batches of GFP^+^ FP^+^ primary blasts ([Figure 1](#fig1){ref-type="fig"}A) that were all CD11b^+^ and contained varying proportions of cells expressing progenitor markers, such as c-Kit, CD34, and FCγRII/III (data not shown). Experiments were repeated using blasts from different primary recipients to ensure identification of consistent features of AML growth and to discount any possible primary donor-specific phenotype. To achieve reliable disease progression while minimizing the number of blasts injected, 100,000 primary AML blasts were transplanted by tail vein injection into non-irradiated secondary recipients. This strategy was critical as potential myelo-ablative conditioning regimens that could favor AML progression and cause hematopoietic and stromal damage were avoided. In all secondary recipients, progressive blast expansion was observed from days 8 to 10 post-transplantation with full BM infiltration typically reached between day 20 and 28, with the variation depending on the source of the primary blasts analyzed. This leukemic engraftment was accompanied by infiltration of the spleen, typically delayed compared to BM infiltration ([Figure 1](#fig1){ref-type="fig"}A). In each mouse, healthy hematopoiesis was progressively lost with AML expansion ([Figure 1](#fig1){ref-type="fig"}B). AML cells, vasculature, and hematopoietic cells were visualized by intravital microscopy (IVM) performed on mouse calvarium BM ([Figure 1](#fig1){ref-type="fig"}C), which has been shown to be representative of long bones' marrow in terms of stroma composition and ability to support functional HSCs and their homing and engraftment ([@bib36], [@bib40]). This approach is minimally invasive and allows longitudinal observation of cellular dynamics (including cell migration, proliferation, and death) taking place within the tissue over the course of hours or days. This approach has been essential for us to uncover previously unappreciated biological processes, such as the ability of HSCs exposed to acute infection to engage wider than normal BM niches ([@bib53]), the migratory behavior of T cell acute lymphoblastic leukemia (T-ALL) cells during disease progression and response to chemotherapy, and T-ALL-induced osteoblastic cells remodeling ([@bib19]). In particular, tile scan images of the entire BM space contained within the calvarium provide a comprehensive, three-dimensional, single-cell resolution overview of the overall organization of the tissue and are therefore ideal to uncover complex remodeling processes that are still poorly understood.Figure 1MLL-AF9-Driven Experimental AML Model and Intravital Microscopy(A) 100,000 primary mTomato (or YFP or non-labeled) and GFP double-positive AML cells are transplanted into non-irradiated secondary recipients, where they progressively infiltrate BM and spleen (n = 5 mice analyzed per time point).(B) AML blasts infiltrate and outcompete non-malignant, healthy BM cells over time. Data shown are from 5 leukemic mice per time point from 2 independent cohorts. Error bars represent mean ± SD.(C) Maximum projection of IVM tile scan image (composite of individual tiles) showing AML cells (mTomato^+^; red) interacting with non-malignant hematopoietic cells (YFP^+;^ yellow) and the vascular microenvironment (Cy5-dextran^+^ blood vessels; cyan).

BM Blood Vessels Are Damaged in AML {#sec2.2}
-----------------------------------

To identify progressive changes of blood vessels *in situ* during AML progression, we performed IVM of Flk1-GFP transgenic mice, in which phenotypic endothelial cells (ECs) express GFP ([Figure 2](#fig2){ref-type="fig"}A) and can be visualized lining BM blood vessels labeled with Cy5-dextran ([Figure 2](#fig2){ref-type="fig"}B). We observed multiple, significant changes in Flk-1 GFP^+^ blood vessels in mice burdened with AML ([Figure S1](#mmc1){ref-type="supplementary-material"}). First, most vessels were narrower than those in control mice ([Figure 2](#fig2){ref-type="fig"}C). Second, they were characteristically further from the endosteal bone surface ([Figures 2](#fig2){ref-type="fig"}D and 2E). Imaging of partially infiltrated mice was consistent with the findings of ([@bib21]) in revealing that AML cells clustered in patches of highly infiltrated areas, whereas the remaining BM space contained only sparse AML cells ([Figure 2](#fig2){ref-type="fig"}F). Blood vessels in highly infiltrated areas appeared unusually barbed and presented dynamic subcellular protrusions toward the parenchyma ([Figure 2](#fig2){ref-type="fig"}F, right panels). High-resolution time-lapse recording of blood vessels at late stages of AML revealed sequential formation and retraction of sprouts ([Figure 2](#fig2){ref-type="fig"}G; [Movie S1](#mmc2){ref-type="supplementary-material"}), similar to those described in response to strong angiogenic stimuli ([@bib14], [@bib27]). However, this sprouting process was never efficient, and we could not detect formation of any steady lateral branches. This is consistent with the increased levels of VEGF-A detected in mice infiltrated with AML ([Figure 2](#fig2){ref-type="fig"}H). We also occasionally observed vascular damage caused by EC breakage into small fragments ([Movie S2](#mmc3){ref-type="supplementary-material"}). Consistent with this observation, we observed abundant 1- to 4-μm-sized cellular debris of endothelial origin (GFP^+^) in the vascular lumen of AML-burdened mice ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B; [Movie S3](#mmc4){ref-type="supplementary-material"}). These debris particles maintained expression of phenotypic endothelial markers, including high levels of CD31 and endomucin ([Figure S2](#mmc1){ref-type="supplementary-material"}C), and contained nucleic acids within an intact membrane ([Figure S2](#mmc1){ref-type="supplementary-material"}D).Figure 2Intravital Imaging of the BM Reveals Blood Vessel Remodeling in AML(A) Flk1-GFP^+^ stromal cells (green) express high levels of CD31.(B) Representative maximum projection of a calvarial area showing Flk1-GFP^+^ ECs lining blood vessels highlighted by Cy-5-dextran. Blue, Cy-5-dextran; Green, Flk1-GFP^+^ cells.(C) Representative maximum projections and respective orthogonal views of Flk1-GFP^+^ vessels (green) in the BM, showing vessels from leukemic mice have reduced diameter and increased distance from bone (arrows). Gray, bone collagen second harmonic generation (SHG).(D) Representative 3D renderings of the surface of Flk1-GFP^+^ vessels (green) with the areas co-localizing with bone highlighted in pink. Dark blue in the background is bone.(E) The contact area between vessels and bone is significantly reduced in AML-infiltrated BM. Data in (B)--(E) are from 5 control and 4 AML mice.(F) Representative tile scan maximum projection (composite of individual tiles) of a Flk1-GFP mouse partially infiltrated with mTomato^+^ AML cells (red). Gray, bone collagen SHG. Time-lapse imaging shows steady and smooth vascular contours (red lines) in lightly infiltrated areas (P1). Instead, vessels in heavily infiltrated areas (P2) have irregular contours (red lines) and show active and inefficient sprouting (red arrows) over time.(G) Selected frames from representative time-lapse data from a heavily infiltrated area showing rapid vascular sprout formation (red arrows) and regression (full time-lapse: [Movie S1](#mmc2){ref-type="supplementary-material"}).(H) VEGF-A levels in serum of control mice (C), mice with AML (AML), and mice with AML treated with combined cytarabine and doxorubicin (post-chemo). n = 4 mice per group. Error bars represent mean ± SEM.

Endosteal Vessels Are Specifically Lost in Mice with AML {#sec2.3}
--------------------------------------------------------

Prompted by our initial observations, we performed in-depth analysis of blood vessels in the endosteal areas of long bones using immunofluorescence of whole, undecalcified long bone sections from healthy and diseased mice ([Figure 3](#fig3){ref-type="fig"}A). This approach allowed us to simultaneously investigate AML-mediated changes in the vasculature of different BM areas: the central marrow diaphysis; the bone-lining endosteum; and the trabecular metaphysis. We were able to detect a significant decrease of vessels in the endosteum and metaphysis over time ([Figures 3](#fig3){ref-type="fig"}B and 3C). The endosteal vessels were significantly, and progressively, lost at both intermediate (40%--50% BM infiltration) and advanced (\>80% BM infiltration) disease stages ([Figure 3](#fig3){ref-type="fig"}C). Notably, vessel loss was specific to these areas and not observed in the diaphysis region, where vessels were either maintained or transiently increased ([Figures 3](#fig3){ref-type="fig"}B and 3C). To investigate the relevance of these observations in humans, we performed additional histological analysis of BM trephine biopsies from AML patients with \>80% infiltration and confirmed that endosteal vessels were decreased ([Figures 3](#fig3){ref-type="fig"}D and 3E). Additionally, endosteal vessels were maintained in a murine model of Notch-driven T-ALL ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), suggesting that the vascular remodeling we observed is specific to AML. These findings pointed to a specific depletion of the functionally unique endosteal endothelium, recently shown to regulate osteogenesis ([@bib34]) and to maintain HSCs ([@bib26], [@bib35]).Figure 3Endosteal and Metaphyseal Vessels Are Decreased in AML(A) Representative maximum intensity projection of a tile scan (composite of individual tiles) of 20-μm-thick sections of undecalcified tibias from wild-type control (top) and fully infiltrated (bottom) mice. Vessels are labeled by laminin and endomucin (Emcn) immunostaining. dp, diaphysis; ed, endosteum; gp, growth plate; mp, metaphysis; soc, secondary ossification center.(B) Representative maximum intensity projections comparing vascular staining in the diaphysis, endosteum, and metaphysis of control (top row) and fully infiltrated (bottom row) mice. Blue, DAPI; gray, bone collagen SHG; green, endomucin^+^ vessels; red, laminin^+^ vessels and extracellular matrix.(C) Quantification of blood vessels in diaphysis, endosteum, and metaphysis at different stages of AML progression. Data were obtained from 11 mice with 0% infiltration (control), 3 mice with 0.2%--0.5% infiltration, 3 mice with 40%--50% infiltration, and 5--10 mice with 80%--95% infiltration from 2 independent cohorts. Error bars represent mean ± SD.(D) Representative images of BM trephine biopsies from control and AML patients stained with anti-von Willebrand factor antibody to mark blood vessels (brown). Yellow dotted lines delineate endosteal area within 20 μm from the bone. Yellow arrowheads point at endosteal vessels and black arrowheads at central marrow vessels.(E) Endosteal vessels are decreased in AML patients. Data were obtained from 6 control and 3 AML patients. Error bars represent mean ± SEM.(F) Central and endosteal AML cells were isolated and analyzed by RNA-seq.(G) Most of the variance in the data is explained by MDS dimensions 1 (60%) and 2 (21%).(H) Multi-dimensional scaling (MDS) plot of distances between gene expression profiles of AML cells and control GMPs. Each dot represents a sample. Data were obtained from 3 AML batches, 3 biological replicates per batch, and 9 control mice.(I) Heatmap of all the genes that are differentially regulated, with false detection rate (FDR) cutoff of 0.05. Gene expression is relative to GMP.(J and K) Gene set enrichment analysis (GSEA) comparing AML cells isolated from central and endosteal BM areas for genes involved in (J) inflammatory response and in (K) the TNF signaling pathway.(L) Volcano plot showing genes that are differentially expressed in endosteal and central AML cells. Red dots represent individual genes that are differentially expressed with a p value cutoff of 0.05. *Cxcl2* is highlighted and is overexpressed in endosteal AML cells.(M) Expression of genes encoding cytokines known to inhibit angiogenesis.(N and O) CXCL2 (N) and TNF (O) levels in central and endosteal BM fluid fractions and in the serum of the same mice. Data were obtained from 9 control and 9 AML-burdened mice.

Because we observed differential remodeling of the microenvironment in AML-burdened mice, we questioned whether they could be triggered by regional variations in leukemia cells. To address this question, we performed RNA sequencing (RNA-seq) analysis on sorted AML cells from trabecular-rich areas (crushed metaphysis) or central BM areas (flushed diaphysis; [Figure 3](#fig3){ref-type="fig"}F). We compared the transcriptome of endosteal and central AML cells originating from three independent primary donors to non-transformed granulocyte macrophage progenitors (GMPs) from the BM of healthy mice. Gene expression and multi-dimensional scale analyses illustrated that each AML batch had its own unique gene expression signature, consistent with clonal evolution of tumor cells, whereas control GMPs were extremely homogeneous ([Figures 3](#fig3){ref-type="fig"}G--3I).

Despite the similarity in gene expression between endosteal and central AML cells, gene set enrichment analysis (GSEA) demonstrated endosteal AML cells were enriched for expression of genes involved in the inflammatory response ([Figure 3](#fig3){ref-type="fig"}J) and tumor necrosis factor (TNF) signaling pathways ([Figure 3](#fig3){ref-type="fig"}K). Furthermore, the anti-angiogenic cytokine *Cxcl2* (also known as MIP-2α or chemokine gro-β; downstream of TNF; [@bib58]) was significantly more expressed in endosteal AML cells ([Figures 3](#fig3){ref-type="fig"}L and 3M). Analysis of TNF and CXCL2 levels in BM fluids confirmed that both cytokines were specifically and highly increased in endosteal areas of AML-burdened mice ([Figures 3](#fig3){ref-type="fig"}N and 3O). These results highlight the importance of inflammation in AML pathogenesis and support a role for CXCL2 and TNF in the remodeling of endosteal vessels.

BM Stroma Is Locally and Progressively Depleted in AML {#sec2.4}
------------------------------------------------------

Flow cytometry analysis ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3H) demonstrated that, although the proportion of ECs in surviving stroma was increased in AML-burdened mice ([Figure S3](#mmc1){ref-type="supplementary-material"}E), the absolute number of ECs was not statistically significantly different ([Figure S3](#mmc1){ref-type="supplementary-material"}F). However, phenotypically defined endosteal ECs (CD31^hi^Endomucin^hi^ or CD31^+^Sca-1^+^) were significantly reduced in diseased mice ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H). To better understand how AML affects overall BM stroma, we imaged chimeric mice bearing membrane-bound Tomato^+^ stroma and wild-type, non-fluorescent hematopoietic cells injected with yellow fluorescent protein (YFP)^+^GFP^+^ double-positive AML blasts. At \>50% BM infiltration, we observed a dramatic reduction of overall stromal cells *in vivo*, including the stroma surrounding blood vessels and adjacent to bone ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Consistent with this pattern, extensive IVM time-lapse (7--12 hr) of these mice revealed that blood vessels underwent abnormal oscillations, suggesting that their anchorage to the surrounding parenchyma had been lost ([Figure S4](#mmc1){ref-type="supplementary-material"}B; [Movie S4](#mmc5){ref-type="supplementary-material"}, arrowheads). Extensive stroma loss was confirmed by flow cytometry analysis of non-chimeric mice, revealing a \>10-fold reduction in the number of CD45^−^ Ter119^−^ cells in the BM of AML-burdened mice ([Figure S4](#mmc1){ref-type="supplementary-material"}C). To better understand the process leading to such dramatic overhaul of BM stroma, we performed live imaging at earlier stages (days 10--12 post-injection of leukemia blasts; 5%--15% infiltration). At these earlier time points, we could compare areas with low and high infiltration within the same mouse ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Here, peri-vascular and endosteal stroma were depleted in highly infiltrated areas, whereas both components maintained a normal appearance in weakly infiltrated areas, suggesting that AML cells remodel the stroma locally after reaching a certain threshold density.

Loss of Healthy Hematopoiesis Is Temporally and Spatially Correlated with Endosteal Remodeling {#sec2.5}
----------------------------------------------------------------------------------------------

Because the endosteal endothelium has been shown to locate next to and sustain osteoblasts ([@bib34]), we expanded our analysis of the endosteal microenvironment to include a focused investigation of osteoblastic cells (CFP^+^ or GFP^+^ cells in Col2.3-CFP/GFP reporter mice, respectively) during AML growth. IVM of the calvarium of Col2.3-GFP mice revealed that GFP^+^ osteoblastic cells were significantly reduced in an infiltration-dependent manner ([Figures 4](#fig4){ref-type="fig"}A and 4B). IVM of chimeras containing CFP^+^ osteoblastic cells, mTomato^+^ healthy hematopoietic cells, and YFP^+^GFP^+^ leukemia revealed that AML cells, as they remodel stroma and vessels locally, also outcompete healthy hematopoietic cells and eliminate osteoblastic cells ([Figures 4](#fig4){ref-type="fig"}C and 4D). This finding indicated that microenvironmental and hematopoietic changes induced by leukemia evolve focally and in parallel. IVM of healthy and highly infiltrated double-transgenic Flk1-GFP/Col2.3-CFP mice confirmed that osteoblasts and endosteal vessels were lost in the presence of AML, whereas central vessels were maintained ([Figure 4](#fig4){ref-type="fig"}E). To understand whether one microenvironment component may be lost first, we analyzed long bone sections from mice at intermediate stages of disease ([Figure 4](#fig4){ref-type="fig"}F). Within the same bone, osteoblasts were significantly decreased only in areas with high levels of leukemic infiltration ([Figure 4](#fig4){ref-type="fig"}G), whereas we could detect loss of endosteal vessels in areas with intermediate levels of infiltration ([Figure 4](#fig4){ref-type="fig"}H). These data suggest that endosteal vessels may be lost earlier than osteoblasts.Figure 4AML Remodels the Endosteal Niche and Outcompetes Normal Hematopoiesis(A) Representative tile scans (composite of individual tiles) of Col2.3-GFP mice transplanted with mTomato^+^ leukemia. Blue, Cy5-dextran^+^ blood vessels; green, Col2.3-GFP^+^ osteoblastic cells; red, mTomato^+^ AML.(B) Automated segmentation and volume calculation (voxels) of osteoblast loss (green line) and leukemia expansion (red line) over time. Data were obtained from 17 mice, from 2 independent cohorts. Error bars represent mean ± SEM.(C) Maximum intensity projection of a tile scan (composite of individual tiles) of a Col2.3-CFP recipient with mTomato^+^ healthy hematopoietic cells and YFP^+^GFP^+^ AML blasts. Leukemia cells (yellow) infiltrate the calvarium and deplete osteoblastic cells (cyan) and healthy hematopoietic cells (red) locally.(D) 2D slice from the area framed in (C) at a depth close to the calvarium surface, including the BM components from (C) and collagen bone SHG (gray). (C and D) Data were obtained from 6 mice.(E) IVM images of representative areas of the calvarium BM of control and AML-infiltrated Col2.3-CFP/Flk1-GFP double-transgenic mice. Cyan, Col2.3-GFP^+^ osteoblastic cells; gray, bone; green, Flk1-GFP^+^ ECs; red, mTomato^+^ AML cells. n = 3 mice.(F) Maximum intensity projection of a representative tile scan (composite of individual tiles) of undecalcified tibia sections from Col2.3-CFP recipients with mTomato^+^ healthy hematopoietic cells (red) and YFP^+^GFP^+^ AML (yellow) blasts. Blue, osteoblasts; cyan, vessels (endomucin^+^); gray, bone. Mice had intermediate levels of AML infiltration. Boxes in P1 and P2 higher magnification images illustrate examples of areas within the same bone with low, high, and intermediate levels of infiltration, used to quantify stroma remodeling.(G and H) Quantification of osteoblasts (G) and endosteal vessels (H). Data were obtained from 3 mice.

We next investigated the hematopoietic changes associated with microenvironment remodeling. Analysis of non-chimeric mice with increasing AML infiltration by flow cytometry showed a progressive decrease of overall normal hematopoietic cells in the BM ([Figure 1](#fig1){ref-type="fig"}B) and more specifically of Lineage^−^, cKit^+^ Sca-1^+^ (LKS) progenitor cell and LKS CD48^−^ CD150^+^ HSC populations ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). Importantly, HSCs in the BM were significantly reduced only at late stages of disease ([Figure 5](#fig5){ref-type="fig"}A), when endosteal and metaphyseal vessels, as well as osteoblastic cells, were all drastically reduced ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Furthermore, whereas LKS cells are lost in areas both distant from (flushed diaphysis) and close to (crushed metaphysis) the bone ([Figure 5](#fig5){ref-type="fig"}B), HSCs are most dramatically lost in the bone-rich metaphysis ([Figure 5](#fig5){ref-type="fig"}C). This observation highlights the association and consequent tandem collapse of endosteal vessels and HSCs at late stages of AML. We also observed that, as disease progresses, the number of HSCs in the spleen increases ([Figures 5](#fig5){ref-type="fig"}D, 5E, and [S5](#mmc1){ref-type="supplementary-material"}B). Notably, this hematopoietic elevation coincides with an increase of splenic ECs ([Figure 5](#fig5){ref-type="fig"}F).Figure 5HSC Dynamics and Hematopoietic Cell Trafficking in BM and Spleen(A) Fold change in LKS cells and HSCs with increasing AML infiltration. HSCs are only lost at late time points, when endosteal remodeling is more dramatic. Data were obtained from 15 mice with 0%--25%, 5 mice with 25%--50%, 6 mice with 50%--75%, and 8 mice with 75%--100% AML infiltration, from 2 independent cohorts. Error bars represent mean ± SEM.(B) LKS cells are significantly decreased in both the diaphysis (Dp flushed) and in the trabecular bone-rich metaphysis (Mp crushed) of AML-burdened mice, with no differences between these two fractions.(C) HSCs are significantly lost in the metaphysis of AML-burdened mice. Data were obtained from 3 control and 4 leukemic mice. Error bars represent mean ± SD.(D) Paired analysis shows a negative correlation between HSC numbers in spleen and BM (1 femur, 2 tibias, and 2 ileac bones).(E) LKS cells and HSC numbers increase in the spleen during AML progression. Data were obtained from 7 mice with 0%--25%, 3 mice with 25%--50%, 2 mice with 50%--75%, and 3 mice with 75%--100% BM infiltration. Error bars represent mean ± SEM.(F) Mice burdened with AML have significantly increased absolute cell numbers of CD31^+^ ECs in the spleen. Data were obtained from 4 control and 5 leukemic mice. Error bars represent mean ± SEM.(G) Time-lapse *in vivo* imaging revealed that, in AML-burdened mice, residual healthy mTomato^+^ cells had increased adhesion to the luminal endothelial surface, particularly in leukemic spleens, when normalized by the frequency of surviving cells (e.g., once divided by 0.699 in a mouse with 30.1% blasts in the BM).(H) Examples of healthy tomato^+^ cells maintaining stable (static) or transient (crawling) adhesion to the splenic endothelium.(I) We observed a significant increase of healthy mTomato+ cells undergoing transendothelial migration (TEM) in the BM of AML-burdened mice, once normalized for the infiltration level.(J) Examples of cells migrating from the tissue to the vascular lumen (intravasation) and in the opposite direction (extravasation) are shown.(C and E) Blue, Cy5-dextran; green, Flk1-GFP^+^ ECs; red, mTomato^+^ healthy hematopoietic cells. Data were obtained from the analysis of 521 (BM) and 588 (spleen) tomato^+^ cells from 3 control and 3 leukemic mice. Error bars represent mean ± SEM.

To reconcile our initial observations on the morphological and structural changes in BM vessels of AML-infiltrated animals ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) with the progressive loss of normal hematopoietic cells ([Figures 5](#fig5){ref-type="fig"}A--5F), we asked whether they could result in increased hematopoietic cell trafficking. We performed paired IVM of BM and spleen in the same AML-burdened and control mice ([Figure S5](#mmc1){ref-type="supplementary-material"}C) and observed increased numbers of healthy hematopoietic cells adhering to ([Figures 5](#fig5){ref-type="fig"}G and 5H; [Movie S5](#mmc6){ref-type="supplementary-material"}) and transmigrating across ([Figures 5](#fig5){ref-type="fig"}I and 5J; [Movie S6](#mmc7){ref-type="supplementary-material"}) endothelial cells in leukemic mice. This pattern of egress may contribute to the loss of BM hematopoiesis. We also observed AML cell clusters that adhered to the endothelial cells on their intravascular surface and compromised blood flow ([Movie S7](#mmc8){ref-type="supplementary-material"}), likely contributing to the observed functional alterations of the endothelium ([@bib52]).

AML-Induced Endosteal Remodeling Regulates HSC Numbers {#sec2.6}
------------------------------------------------------

To confirm that HSC loss from the BM was due to the microenvironmental changes we observed rather than a direct effect of leukemia cells on the stem cells, we asked whether the remodeled BM would still have the capacity to support homing of HSCs. To this end, we transplanted DiD-labeled HSCs into lethally irradiated control and leukemic mice ([Figure 6](#fig6){ref-type="fig"}A). Two days after transplantation, significantly lower numbers of HSCs were found in the BM of leukemic mice ([Figure 6](#fig6){ref-type="fig"}B). This observation suggests that AML leads to a specific collapse of HSC-supportive BM niches, as previously hypothesized for B cell acute lymphoblastic leukemia ([@bib7]). We then investigated whether maintenance of BM endosteal endothelium during AML growth would protect HSCs in endosteal areas. To address this, we treated leukemic mice with deferoxamine (DFO), a clinically approved prolyl-4-hydroxylase (PHD) inhibitor normally administered as an iron chelator but also recently described to induce endosteal vessel expansion through enhancement of hypoxia-inducible factor 1α (Hif-1α) stability and activity ([@bib34]). DFO or control (PBS) treatment started 8 days post-injection of AML blasts and continued until day 22 post-transplantation, at which time point the BM was heavily infiltrated ([Figure 6](#fig6){ref-type="fig"}C). DFO-treated mice had similar numbers of AML cells in the BM ([Figure 6](#fig6){ref-type="fig"}D) and similar disease progression ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B) and survival ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Endosteal blood vessels were increased in DFO-treated mice ([Figures 6](#fig6){ref-type="fig"}E and 6F). Consistent with our hypothesis that HSC numbers depend on endosteal vessels, we observed that leukemic mice receiving DFO had significantly higher numbers of HSCs in the trabecular-rich metaphysis, but not in flushed diaphyseal BM ([Figures 6](#fig6){ref-type="fig"}G and 6H). A direct positive effect of DFO on HSC numbers was excluded through *in vitro* culture ([Figures S6](#mmc1){ref-type="supplementary-material"}D--S6G). To further investigate the clinical utility of DFO, we investigated the homing of HSCs in mice infiltrated with AML and treated with DFO or vehicle ([Figure 6](#fig6){ref-type="fig"}I). In line with our hypothesis, DFO-treated mice supported HSC homing to the BM ([Figure 6](#fig6){ref-type="fig"}J). Altogether, these data suggested that rescue of endosteal vessels can support HSCs despite AML growth and improve HSC homing.Figure 6The Endosteal Remodeling in AML Regulates HSC Numbers(A) 12,000 sort-purified HSCs were labeled with DiD and transplanted into irradiated control or AML-recipient mice. 2 days after transplantation, DiD^+^ HSCs resident in the BM were quantified by flow cytometry.(B) Homing of transplanted DiD^+^ HSCs was significantly impaired in the BM of AML-burdened mice. n = 3 control and 3 leukemic mice.(C) DFO treatment regimen.(D--F) DFO did not affect the total number of AML cells (D) but increased the number of endosteal vessels (E and F). Blue, AML cells; gray, collage bone SHG; green, endomucin^+^ vessels; red, laminin^+^ vessels and extracellular matrix. Each dot is a mouse.(G) AML-burdened mice treated with DFO had more HSCs remaining in the metaphysis in comparison to controls.(H) Quantification of flow cytometry analysis of DFO treated and control (PBS) mice, showing similar numbers of HSCs in the diaphysis (Dp flushed) but a significant increase of HSCs remaining in the metaphysis (Mp crushed).Data are representative of (G) and obtained from (H) 4 mice treated with PBS and 5 treated with DFO.(I) Mice transplanted with AML cells were treated with either PBS or DFO. At full infiltration, mice were lethally irradiated and transplanted with DiD-labeled HSCs that had not been exposed to DFO.(J) DFO improves the homing of transplanted DiD^+^ HSCs in the BM of AML-burdened mice. Data were obtained from 4 recipients treated with PBS and 4 recipients treated with DFO.In (B--J), error bars represent mean ± SEM.

Rescue of Endosteal Vessels Improves Chemotherapy Efficiency {#sec2.7}
------------------------------------------------------------

The observed remodeling of blood vessels in AML-burdened mice and especially the loss of endosteal vessels led us to hypothesize that these changes could not only contribute to outcompeting healthy hematopoiesis but also compromise delivery of chemotherapy. In a xenograft transplantation model of AML, chemo-resistant leukemia cells were previously shown to locate near the endosteum ([@bib25]). This suggests that localization of leukemia cells in areas of BM stripped of their vasculature could provide them with a survival advantage. In our model, trabecular areas were enriched for AML cells both at early and late stages of infiltration and following induction chemotherapy ([Figure S7](#mmc1){ref-type="supplementary-material"}A). We hypothesized that, by rescuing blood vessels in endosteal areas, we could increase chemotherapy delivery and therefore efficacy. To test this prediction, we utilized Fbxw7^iΔEC^ mutant mice, in which tamoxifen administration leads to increased activation of Notch signaling specifically in ECs, thereby increasing the number of endosteal vessels and arterioles ([@bib35], [@bib51]). Fully infiltrated Fbxw7^iΔEC^ mutants had increased numbers of endosteal vessels ([Figures 7](#fig7){ref-type="fig"}A and 7B). At this point, we treated both Fbxw7^iΔEC^ and control mice with an adapted form of clinical induction chemotherapy (cytarabine \[Ara-C\] and doxorubicin \[Doxo\]; [@bib60]; [Figures 7](#fig7){ref-type="fig"}C and [S7](#mmc1){ref-type="supplementary-material"}B--S7D). In agreement with a previous report ([@bib22]), we observed significant chemotherapy-induced damage to the BM vasculature, including endosteal vessels, in both control and mutant mice ([Figure 7](#fig7){ref-type="fig"}D). We observed that, after treatment, the Fbxw7^iΔEC^ mutants had reduced numbers of surviving AML cells in the BM ([Figure 7](#fig7){ref-type="fig"}E), delayed relapse ([Figure 7](#fig7){ref-type="fig"}F), and increased survival ([Figure 7](#fig7){ref-type="fig"}G). Altogether, these data suggest that the rescue of endosteal vessels before induction chemotherapy can improve its efficacy.Figure 7Rescue of Endosteal Vessels Increases Induction Chemotherapy Efficiency(A) Immunofluorescence staining of endosteal areas showing a significant increase of blood vessels in Fbxw7^iΔEC^ mutants infiltrated with AML. Gray, bone collagen SHG; green, endomucin^+^ vessels; red, laminin^+^ vessels and extracellular matrix.(B) Quantification of the results obtained from 5 control mice and 4 Fbxw7^iΔEC^ mice.(C) Scheme of treatment regimen used to delete Fbxw7 in ECs.(D) Maximum projections of immunofluorescence staining of representative endosteal areas showing dilated blood vessels (green, endomucin; red, laminin) after therapy in both control and mutant animals, as well as surviving AML cells (cyan) scattered through the tissue. Data are representative of 3 control mice and 3 Fbxw7^iΔEC^ mutants.(E) After chemotherapy, there was a significant decrease of surviving AML cells in Fbxw7^iΔEC^ mutants, where the endosteal vessels had been rescued. Data were obtained from 8 control mice and 5 Fbxw7^iΔEC^ mutants.(F) Although disease progression before chemotherapy is similar, relapse is delayed in Fbxw7^iΔEC^ mutants. n = 3 Cre^−^ and 6 Cre^+^ mice.(G) Kaplan-Meyer curve showing improved survival in treated Fbxw7^iΔEC^ mutants transplanted with AML. n = 5 Cre^−^ and 6 Cre^+^ mice.In (B--F), error bars represent mean ± SEM.

Discussion {#sec3}
==========

Our study describes how AML cells focally and progressively remodel BM vasculature to transform HSC niches into preferential leukemia microenvironments. In particular, BM vasculature editing is anatomically diverse, with endosteal vessels being progressively obliterated, whereas central marrow vessels survive, albeit with compromised function. The two main consequences of this are HSC loss specifically from endosteal areas and survival of leukemia cells following chemotherapy treatment. Intravital microscopy provided us with the unique opportunity to perform detailed, longitudinal analysis of progressive changes occurring across the entire vascular bed irrigating the calvarium BM. This approach identified dynamic and area-specific changes previously overlooked by studies of AML patient samples that focused on central BM areas or examined vasculature as a whole ([@bib1], [@bib16], [@bib23], [@bib45]). Consistent with initial reports of the angiogenic potential of AML cells ([@bib11]), we observed increased levels of VEGF-A in leukemic mice and endothelial cell dynamics resembling angiogenic sprouting ([@bib14]). However, these sprouts never gave rise to the formation of new vessels, which might be driven by VEGF-A-mediated tip cell competition ([@bib27]). The expression of additional angiogenic factors by AML cells might also explain the disappointing results of the clinical trials testing anti-angiogenic therapies for AML patients ([@bib12], [@bib44], [@bib62]). Furthermore, the combination of high-resolution intravital microscopy and quantitative flow cytometry analysis of BM ECs showed that the apparent relative increase in ECs is a consequence of the overall loss of BM stroma. This finding contrasts with observations made in solid tumors, where most often accumulation of stroma and pro-fibrotic changes are reported adjacent to the cancerous cells ([@bib50]).

Whereas central marrow vessels were maintained during AML infiltration, we observed dramatic remodeling of endosteal vessels. These vessels were initially remodeled in areas containing foci of disease but eventually almost disappeared from the BM of heavily infiltrated animals. AML cells in endosteal areas were enriched in inflammatory and TNF gene signatures and expressed higher levels of CXCL2. Both TNF and CXCL2 levels were locally increased in endosteal areas. This is consistent with the recently described role of TNF in vascular destruction ([@bib28]). Furthermore, CXCL2 is an angiogenesis inhibitor ([@bib5]) that has also been shown to mobilize HSCs from the BM ([@bib13]) and to be associated with poor prognosis and reduced survival in AML ([@bib29]). Overall, our data support future investigation of the role of CXCL2 and TNF in the vascular remodeling and loss of HSCs induced by AML in endosteal regions.

In parallel with endosteal vessel remodeling, we also observed a similar pattern of osteoblastic cell loss. It was shown previously in a mouse model of myeloproliferative neoplasia based on widespread induction of BCR-ABL that aberrant differentiation of mesenchymal progenitor cells led to an expansion of dysfunctional osteoblasts associated with loss of HSC activity ([@bib54]). Here, we observed the depletion of not only osteoblasts but also endosteal vessels. This interpretation does not exclude "re-wiring" of mesenchymal progenitors; however, it highlights a dramatic imbalance between osteoblast generation and loss. Most importantly, our findings are consistent with studies that reported decreased numbers and activity of osteoblasts in patients with AML ([@bib32]). Using a complementary experimental model, Hanoun and colleagues have shown that sympathetic neuropathy promotes the expansion of nestin^+^ mesenchymal stem cells and limits their differentiation into NG2^+^ cells in the arteriolar niche of mice with AML ([@bib16]). These data, when combined with our results presented here, suggest that fast-growing AML depletes stroma with niche function.

By combining longitudinal intravital microscopy and immunofluorescence analyses with the study of mice with intermediate disease burden, we obtained detailed temporal information on the progression of AML-induced BM remodeling. We have recently reported a similar collapse of the osteolineage at late stages of T-ALL ([@bib19]). In contrast with AML, here we observed that endosteal vessels are not lost in T-ALL, highlighting the specificity of microenvironment remodeling in different types of leukemia. However, analysis of human AML samples revealed endosteal vessel remodeling in unrelated AML types. Our findings, together with clinical evidence demonstrating that cytopenias are more common and severe in AML than in T-ALL, suggests that endosteal vessel remodeling may be the cause of dramatic cytopenias associated with AML.

Splenomegaly, though rare in AML patients, is present and accompanied by extramedullary hematopoiesis in experimental mouse models of acute leukemia. In our model, increased EC numbers in the spleen likely form *de novo* vascular niches able to support HSCs and extramedullary hematopoiesis, consistent with the recent discovery of a peri-sinusoidal niche in the spleen ([@bib24]). Moreover, we were able to detect functional changes in endothelial cells, allowing for greater adhesion and transendothelial migration of hematopoietic cells in diseased mice. This is consistent with a recent study highlighting increased vascular permeability in AML ([@bib47]). These changes likely contribute to the egress of healthy hematopoietic cells from the BM ([@bib3], [@bib26]) and relocation to the spleen.

Consistent with previous studies indicating that HSCs are relatively resistant to AML invasion ([@bib6], [@bib41]), we observed that HSC loss occurs at late stages of disease infiltration, when we show that endosteal remodeling is more evident. Treatment with DFO significantly increased the number of endosteal blood vessels together with endosteal HSCs and improved the homing of HSCs to the BM. DFO has been reported to limit leukemic cell proliferation and to potentiate the effect of differentiation therapies in AML through iron chelation ([@bib4]). Here, no significant changes in the number of AML cells or disease progression were observed in DFO-treated mice. This suggests that potential off-target effects of DFO on AML proliferation did not play a major role in the protection of HSCs.

Apart from leading to HSC loss, elimination of endosteal vessels may favor AML cells during chemotherapy administration by providing them with a vessel-poor microenvironment where drug delivery would likely be challenged and/or inefficient and therefore would foster chemo-resistance. Consistent with our hypothesis, chemo-resistant AML has been shown to initiate relapse from endosteal areas ([@bib25]). Our genetic approach showed that endosteal vessels can be rescued in AML-burdened animals and, in doing so, the efficacy of chemotherapy treatment increases. Our study suggests that induction of endosteal vessels and vascular normalization are promising avenues to both safeguard residual healthy hematopoiesis and improve chemotherapy treatment of AML patients.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Biotin anti-mouse CD3eBioLegend100304Biotin anti-mouse CD4BioLegend100404Biotin anti-mouse CD8aBioLegend100704Biotin anti-mouse Ter119BioLegend116204APC/Cy7 anti-mouse Ter-119BioLegend116223APC/Cy7 anti-mouse CD45BioLegend103116Biotin anti-mouse/human CD45R/B220BioLegend103204Biotin anti-mouse Ly6GBioLegend127604Biotin anti-mouse CD11bBioLegend101204APC/Cy7 anti-mouse/human CD11bBioLegend101226APC anti-mouse/human CD11bBioLegend101212PE/Cy7 anti-mouse/human CD11bBioLegend101216APC anti-mouse CD117 (c-Kit)BioLegend101212APC/Cy7 anti-mouse CD117 (cKit)BioLegend105826PerCP/Cy5.5 anti-mouse Ly6a/E (Sca-1)BioLegend108124Anti-Mouse CD34 eFluor 660eBioscience50-0341-82APC anti-mouse CD34BioLegend128612PE-Cy7 anti-mouse CD16/32BioLegend101318BV650 anti-mouse CD150 (SLAM)BioLegend115931PE/Cy7 anti-mouse CD48BioLegend103424Biotin anti-mouse CD31BioLegend102504PE/Cy7 anti-mouse CD31BioLegend102524Anti-Mouse Endomucin eFluor 660eBioscience50-5851-82PE/Cy7 StreptavidineBioscience405206Streptavidin Pacific OrangeInvitrogenS32365Rat Anti-Mouse Endomucin antibody (V.7C7)Santa-Cruzsc-65495Rabbit Anti-LamininSigma-AldrichL9393Rabbit anti-GFPAbcamab6556Goat anti-Rabbit IgG (H+L) Alexa Fluor 488Thermo ScientificA-11034Goat anti-Rat IgG (H+L) Alexa Fluor 633Thermo ScientificA-21094Anti-Human Factor VIII-Related AntigenDAKON1505**Bacterial and Virus Strains**pMSCV-MLL-AF9-IRESGFPgift from Steve Lane (QIMR Barhofer, Brisbane) Somervaille & Cleary. Cancer Cell 10, 257-268 (2006).N/ANotchICNΔRamΔPGift from Jon C. Aster (Harvard Medical School) and Warren S. Pear (University of Pennsylvania) ([@bib2])N/A**Biological Samples**See table below in "Human trephine biopsies"N/AN/A**Chemicals, Peptides, and Recombinant Proteins**Deferoxamine mesylate saltSigma-AldrichD9533TamoxifenSigma-AldrichT5648-1GCollagenase, Type I, powderGIBCO17018029Cy5-Dextran 500 kDNanocsDX500-S5-1Recombinant Murine SCFPeprotech250-03Recombinant Human IL-6Peprotech200-06Recombinant murine TPOPeprotech315-14Recombinant murine Flt-3 ligandPeprotech250-31LStemSpan Serum Free Expansion MediumSTEMCELL Technologies09650ProLong Diamond Antifade MountantThermo ScientificP36961BD Calibrite 3 Beads Unlabeled, FITC, PE, and PerCP BeadsBD Biosciences340486Vybrant DiDInvitrogenv22887Streptavidin MicrobeadsMiltenyi Biotech130-048-101**Critical Commercial Assays**Mouse VEGF DuoSet ELISAR&D SystemsDY493Mouse TNF-alpha DuoSet ELISAR&D SystemsDY410Mouse CXCL2/MIP-2 DuoSet ELISAR&D SystemsDY452NucBlue Fixed Cell ReadyProbes ReagentLife TechnologiesR37606SYTO 17 Red Fluorescent Nucleic Acid StainLife TechnologiesS7579**Deposited Data**RNaseq data for endosteal AML cells, central AML cells and GMPsGEO: [GSE105159](ncbi-geo:GSE105159){#intref0010}<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE105159>**Experimental Models: Cell Lines**LinXEGift from H. Brady (Imperial College) ([@bib10], [@bib15]).N/A**Experimental Models: Organisms/Strains**C57BL/6Charles RiverN/AFlk1-GFP micegift from Alexander Medvinsky (University of Edinburgh) ([@bib61])PU1-YFP micegift from Claus Nerlov (University of Oxford) ([@bib31])Col2.3-CFP micegift from David Rowe (University of Connecticut Health Center) ([@bib46])Col2.3-GFP micegift from David Rowe (University of Connecticut Health Center) ([@bib19])mT/mG mice[@bib43]Fbxw7^lox/lox^ Cdh5(PAC)-CreERT2^T/+^ miceGift from R. Adams and A. Kusumbe**Software and Algorithms**Fiji/ImageJfiji.sc/N/AZEN blackZeissN/ADefiniens Developer 64DefiniensN/AImarisBitplaneN/AGraphPad PrismGraphPad SoftwareN/AFlowJoTree StarN/AMatlabMathworksN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Cristina Lo Celso (<c.lo-celso@imperial.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

All animal work was in accordance with the animal ethics committee (AWERB) at Imperial College London, UK and UK Home Office regulations (ASPA, 1986). Flk1-GFP mice were a gift from Alexander Medvinsky (University of Edinburgh) ([@bib61]), PU1-YFP were a gift from Claus Nerlov (University of Oxford) ([@bib31]). C57BL/6 mice were from Harlan UK Ltd; Col2.3-GFP ([@bib19]), Col2.3-CFP ([@bib46]), and mT/mG ([@bib43]) mice were bred and housed at Imperial College London, according to institutional guidelines. Animals were housed in a barrier facility, under a 14-hour light / 10-hour dark cycle and temperature-controlled environment with standard diet and water *ad libitum*. Male and female mice \> 6 weeks old were used.

### AML experimental model {#sec4.3.2}

To generate disease traceable by both flow cytometry and microscopy, GMPs were sorted from C57/B6 wild-type, mT/mG or PU.1-YFP mice. GMPs were transduced with pMSCV-MLL-AF9-GFP-based retroviruses as described in ([@bib33]) and then transplanted into sub-lethally irradiated mice. \> 8 weeks post transplantation, recipient mice developed leukemia characterized by multi-organ infiltration of leukemic blasts. GFP^+^ cells were then harvested from BM and spleen and stored. Blasts from each primary recipient were labeled as a separate batch. Primary blasts from different mice were thawed, suspended in phosphate balanced salt solution (PBS) and 100,000 viable cells were transplanted through tail vein injection into secondary, non-conditioned recipient mice. In some instances secondary blasts were used. Progressive blast expansion was observed from day 8-10 and full BM infiltration was typically reached between day 20 and 28, depending on the primary blasts analyzed. This was accompanied by infiltration of the spleen, typically delayed compared to BM infiltration.

### T-ALL experimental model {#sec4.3.3}

T-ALL was generated as described in detail in ([@bib19], [@bib18]). Briefly, fetal liver cells were transduced with NotchICNΔRamΔP-based retrovirus. 1 × 10^6^ DsRed^+^ fetal liver cells were transplanted into lethally irradiated recipients. Upon onset of primary disease (6-25 weeks), DsRed^+^ blasts were harvested and cryopreserved. 10,000 primary blasts were transplanted into sub-lethally irradiated recipients, leading to full BM infiltration in 28 days. Secondary blasts were cryopreserved. 50,000 secondary blasts were thawed, Ficoll purified and injected into non-irradiated tertiary recipients used for experiments. Disease progression was monitored through sampling of peripheral blood. Mice at different stages of infiltration were sacrificed and bones harvested for immunofluorescence.

### Human samples {#sec4.3.4}

Human trephine biopsies were obtained from patients after informed consent had been obtained, under full ethical approval by the Alfred Hospital, the Peter MacCallum Cancer Centre Human Research Ethics Committee, and St. Vincent's Hospital Melbourne. Information about control and AML samples is provided bellow.\#ControlDiagnosis**1**Primary CNS lymphoma**2**Diffusive large B cell lymphoma**3**Mantle cell lymphoma**4**Non-hodgkin lymphoma**5**Non-hodgkin lymphoma**6**Non-hodgkin lymphoma\#AMLWHO classificationCytogeneticsBlasts**1**Acute monoblastic and monocytic leukemiat(10;11)94%**2**Therapy-related acute myeloid leukemiat(9;11)88%**3**Acute promyelocytic leukemiat(15;17)83%

Method Details {#sec4.4}
--------------

### Drug treatments {#sec4.4.1}

The sample size required for animal experiments was based on preliminary data.

For DFO treatment, daily 100mg/kg deferoxamine mesylate (DFO; Sigma) was administered I.P. from day 8 until day 22 post-transplantation of AML blasts, at which time mice were sacrificed and their BM analyzed. Control mice were injected I.P. with 100μl of PBS.

Induction chemotherapy for AML was administered when BM infiltration was over 50% by injecting 100mg/kg cytarabine (Ara-C) I.V. for 5 days and 3mg/kg doxorubicin (Doxo) for 3 days. Ara-C was co-delivered with Doxo on days 1 to 3 and alone on days 4 and 5, mimicking the 7+3 regimen used in AML patients ([@bib60]). Both drugs were purchased from Sellekchem, MA or obtained from the Imperial College Healthcare NHS Trust.

For EC-specific deletion of Fbxw7, tamoxifen (500 μl/mouse I.P.; Sigma) was given daily to Fbxw7^lox/lox^ Cdh5(PAC)-CreERT2^T/+^ (Fbxw7^iΔEC^) mice and to control Fbxw7^lox/lox^ and WT mice. In experiments where relapse and survival were analyzed, tamoxifen was given daily between day 10 and 20 post-transplantation, at which point chemotherapy was initiated. Blinding was done for the tamoxifen studies.

### BM chimeras {#sec4.4.2}

To generate chimeras, whole BM cells were obtained from femurs and tibia of wild-type or mT/mG donor mice, diluted in PBS and transplanted intravenously into lethally irradiated (two doses of 5.5 Gy separated by 3 hours) mT/mG, Col2.3-CFP or Flk1-GFP recipient mice at a dose of 1.5x10^6^ cells/mouse. Mice were kept on baytril-treated water for five weeks following transplantation. \> 95% chimerism was confirmed after 8 weeks and at that point mice were injected with AML cells and used for intravital imaging experiments.

### Flow cytometry {#sec4.4.3}

For hematopoietic and leukemic cell analysis, bones were crushed in PBS with 2% fetal bovine serum and the cells, filtered through a 40 μm strainer and stained. In some instances, the metaphysis of tibias and femurs were separated and crushed, while the diaphysis was flushed. Cells from crushed metaphysis and flushed diaphysis were then stained and analyzed separately. For stroma analysis, tibias and femurs were crushed, digested with collagenase I (Worthington, UK) at 37°C, for 20min with 110rpm agitation, and the obtained cells were filtered through a 70 μm strainer and stained. The following fluorochrome-conjugated or biotinilated primary antibodies specific to mouse were used: CD3e (145-2C11), CD4 (GK1.5), CD8a (53-6.7), Ter119 (TER119), B220 (RA3-6B2), Ly6G (RB-68C5), CD11b (M1/70), cKit (2B8), Sca-1 (D7), CD34 (RAM34), CD16/32 (93), CD150 (TC15-12F12.2), CD48 (HM48-1), CD31 (MEC13.3) all from Biolegend, and endomucin (V.7C7) from eBiosciences. For secondary staining, streptavidin Pacific Orange (Invitrogen) and streptavidin PE Cy7 (Biolegend) were used. Live and dead cells were distinguished using 4,6-diamidino-2-phenylindole (DAPI, Invitrogen). To detect nucleic acids, the cell-permeant SYTO^®^ 17 Red Fluorescent Nucleic Acid Stain (Molecular Probes) was used. Calibrite Beads (BD Biosciences) were used to determine absolute cell counts, as previously described ([@bib17]). Cells were analyzed with a LSR Fortessa, sort-purified using a FACSAria III (BD Biosciences) and data were analyzed with FlowJo (Tree Star).

### HSC transplantation and homing analysis {#sec4.4.4}

Tibias, femurs, ileac bones, vertebrae and sternum were harvested from donor mice, crushed and filtered through a 40 μm strainer. Whole BM cells were labeled with a cocktail of biotinilated lineage antibodies (CD3, CD4, CD8, Ter119, B220, Ly6G, CD11b) and streptavidin magnetic Microbeads (Miltenyi Biotech) to perform a lineage depletion using the MACS^®^ Column Technology (Miltenyi Biotech). The lineage-depleted sample was stained and sorted for phenotypic HSCs, defined as lineage^-^cKit^+^Sca-1^+^CD48^-^CD150^+^ cells. HSCs were centrifuged, suspended in PBS and incubated with Vybrant^®^ 1,1'-dioctadecyl-3,3,3′-tetramethylindodicarbocyanine perchlorate (DiD) (ThermoFisher Scientific) for 10 min, at 37°C. After washing, 5,000 to 12,000 DiD-labeled HSCs were transplanted per mouse via tail vein injection. Control and leukemic recipient mice had been previously lethally irradiated (two irradiations of 5.5Gy, 3 hours apart). 2 days after transplantation, recipient mice were sacrificed and femurs, tibias and the spleen harvested. DiD^+^DAPI^-^cKit^+^Sca-1^+^CD48^-^CD150^+^ cells were detected by flow cytometry.

### LKS culture and DFO *in vitro* treatment {#sec4.4.5}

Lineage depletion was performed as described above. Live lineage^-^cKit^+^Sca-1^+^ (LKS) cells were sorted and plated at a density of 15.000 cells per well in a 48-well plate. Cells were maintained in StemSpan media (Stem Cell Technologies) with added 50ng/μl SCF, 10ng/μl IL-6, 10ng/μl TPO and 20ng/μl Flt3 (all from Peprotech). LKS cells were incubated with 0.5μM, 5μM, 50μM and 500μM DFO. After two days, cells were harvested, stained and the number and frequency of DAPI^-^cKit^+^Sca-1^+^CD48^-^CD150^+^ HSCs analyzed by flow cytometry.

### RNA sequencing and analysis {#sec4.4.6}

RNA-seq was performed as described previously ([@bib59], In Press, *Leukaemia*). Mice were transplanted with primary AML cells from 3 different donors (batch_1\_BM_mTmG, batch_3\_BM_mTmG and batch_19_spleen_mTmG). Upon full infiltration, tibias and femurs were harvested and metaphysis and diaphysis separated using scissors. Endosteal AML cells were isolated by crushing the metaphysis and sorting DAPI^-^GFP^+^mTomato^+^ cells. Central AML cells were isolated by flushing the diaphysis and sorting DAPI^-^GFP^+^mTomato^+^ cells. The control population, GMPs, was sorted from whole BM of age- and sex-matched wild-type mice. Total RNA was extracted using RNeasy^®^ Mini Kit (QIAGEN, Hilden, Germany). The extracted RNA was analyzed on the Agilent 4200 Tapestation prior to library preparation. High quality RNA with RIN values greater than 9 was used for downstream application. 3′mRNA-sequencing libraries were prepared from 100ng of total RNA using the QuantSeq 3′ mRNA-Seq Library Prep Kit (Lexogen) according to the manufacturers instructions and sequenced on a NextSeq 500 (Illumina). The single-end 75bp were demultiplexed using CASAVAv1.8.2 and Cutadapt (v1.9) was used for read trimming. The trimmed reads were subsequently mapped to the mouse genome (mm10) using HISAT2. FeatureCounts was used for read counting ([@bib38]) after which differential gene expression analysis was performed using Voom-LIMMA packages ([@bib37]). GSEA2-2.2.2 was used for Gene set enrichment analysis (GSEA) ([@bib39], [@bib57]).

### Enzyme-linked immunosorbent assay (ELISA) {#sec4.4.7}

To obtain BM supernatants, tibias and femurs were harvested from control and AML-burdened mice. With scissors, the metaphysis and diaphysis of long bones were separated. To obtain *flushed BM supernatant,* 70μl of PBS were flushed through each diaphysis, collected and reflushed; then, cells were excluded by centrifugation at 400 g for 5min; the supernatant was collected and any remaining cells excluded by centrifugation at 500 g for 5min. To obtain *crushed BM supernatant*, the metaphyses were gently crushed in 150μl of PBS, and the supernatant isolated by centrifugation as described above. Serum was prepared by collecting blood through cardiac puncture after terminal anesthesia with pentobarbital; blood was then left at 4°C for 3 hours or more to allow clot formation and centrifuged at 12,000 g for 10min at 4°C; the supernatant (serum) was then transferred to a new eppendorf tube. BM supernatants and serum were stored at −20°C until used for ELISA. DuoSet ELISAs (R&D Systems) were performed according to the manufacturer's instructions.

### Intravital microscopy {#sec4.4.8}

Intravital microscopy was performed using a Zeiss LSM 780 upright confocal microscope equipped with Argon (458, 488 and 514 nm), a diode-pumped solid-state 561 nm laser and a Helium-Neon 633 nm, a tunable infrared multiphoton laser (Spectraphysics Mai Tai DeepSee 690-1020 nm), 4 non-descanned detectors (NDD) and an internal spectral detector array. In some cases a Leica SP5 was used instead. Live imaging of the calvarium BM was done as described in ([@bib19]) and ([@bib55]). The spleens of live mice were imaged under general, terminal anesthesia. Anesthesia was induced and maintained with isoflurane in medical O~2~ (4% isoflurane in 4L/min O~2~ for induction and 1%--2% isoflurane in 1L/min O~2~ for maintenance), throughout the procedure. Mice were placed in the right lateral decubitus position and a small section of hair was removed from the left flank. A 5-8mm abdominal incision on the left flank above the spleen was used to expose the surface of the spleen, which was mechanically stabilized with a gentle vacuum using a coverslip vacuum chamber similar to that used in ([@bib20]). A drop of water was placed on top of the chamber coverslip and the spleen was imaged using a long working distance W Plan-Apochromat × 20 DIC water immersion lens (1.0 N.A.). Blood vessels were labeled with 80 μL of 8mg/ml 500kD Cy5-Dextran (Nanocs, MA).

Second harmonic signal was excited at 860-880nm and detected with external detectors. CFP signal was excited at 870nm or 458nm and detected using external or internal detectors; GFP signal: excitation at 880nm or 488nm, external or internal detectors; YFP signal: excitation at 488nm or 514nm, internal detectors. mTomato/DsRed and Cy5 signals were respectively excited at 561nm and 633nm and detected using internal detectors. To simultaneously detect SHG, CFP, mTomato, YFP and Cy5 signals in chimeras, lambda acquisition and online fingerprinting were used and the signal collected using an external 32-channel gallium arsenide phosphide (GaAsP) detector. The reference spectra were acquired in different BM areas of the same mouse.

### Immunofluorescence of undecalcified long bone sections {#sec4.4.9}

Tibias, femurs and hips were harvested and fixed overnight in periodate-lysine-paraformaldehyde (PLP) fixative, at 4°C. The bones were then washed with 0.1M phosphate buffer, immersed in sucrose (10%--30% gradient) for 48h for cryoprotection, frozen in optimal cutting temperature (OCT) compound (TissueTek) and kept at −80°C. Sections were obtained using a cryostat (Leica) and the Cryojane tape transfer system (Leica microsystems). Slides were either kept at 4°C and used in the following week or stored at −80°C. For staining, slides were re-hydrated in PBS, permeabilised in 0.1% Triton X-100, blocked in 5% goat serum and incubated with primary antibodies overnight, at 4°C. After washing in PBS, slides were incubated with secondary antibodies, counter-stained with DAPI, washed in 0.1% Triton X-100 and mounted with Prolong Diamond antifade (Invitrogen). The following antibodies were used: endomucin (V.7C7, Santa Cruz, 1:100), laminin (L9393, Sigma-Aldrich, 1:50), GFP (ab6556, Abcam, 1:500), goat anti-rat IgG Alexa Fluor 488 (Life Technologies, 1:400), goat anti-rabbit IgG Alexa Fluor 633 (Life Technologies, 1:400). Images were obtained using a Zeiss LSM 780 upright confocal/two-photon combined microscope (see intravital microscopy section) and analyzed using Fiji/ImageJ.

### Human trephine biopsies {#sec4.4.10}

De-waxed human trephine biopsy sections, obtained under ethical approval from Alfred Hospital, Melbourne, were stained with vWF antibody (Ready-to-Use, DAKO), counterstained and mounted for viewing. Representative areas of each section were captured and analyzed by two independent researchers.

### Image processing and quantification {#sec4.4.11}

ZEN black (Zeiss, Germany) software was used to stich three-dimensional BM and spleen tilescans (tilescans represent individual tiles stitched together to form a composite). FIJI/ImageJ was used to visualize, register ([@bib49]) and process raw data. FIJI was used to manually crop out autofluorescent signal from out of the tissue. Cell tracking was performed using FIJI and cells enumerated in the ROI manager. Automated cell segmentation, and volume measurements were performed in Definiens (Definiens Developer 64, Germany) using local heterogeneity segmentation ([@bib30]) to isolate Flk1-GFP^+^, Col2.3-GFP^+^ and mTomato^+^ AML cells. Vessel-bone colocalization was analyzed using Imaris (Bitplane, Switzerland). After creating a surface for Flk1-GFP^+^ signal and a surface for bone (SHG) signal from half tilescans, the Imaris XTension "Surface surface colocalization" was used.

Endosteal vessels were quantified in immunofluorescence sections by dividing the length of blood vessels (marked with laminin and endomucin) in contact with the bone surface (SHG signal) by the total length of the endosteal surface. Metaphyseal and diaphysial vessels were quantified by thresholding the vascular signal in the metaphysis and diaphysis and quantifying the area occupied by blood vessels. Microvascular density was quantified manually counting blood vessels and dividing the obtained counts by the total area.

Vessels oscillation was quantified in FIJI. After registration, maximum projections of 3D movies were produced. In each movie, 2 regions of interest (ROI) were selected and combined in a single object. After clearing the outside of ROIs, a Gaussian filter and a bleach correction were applied and the vessel movement automatically tracked using the plugin TrackMate.

Quantitation and Statistical Analyses {#sec4.5}
-------------------------------------

Raw data was visualized and processed using Microsoft Excel, MATLAB and GraphPad Prism (GraphPad Software Inc.). Group means were compared using the unpaired Student's t test. For multiple comparisons, one-way ANOVA with post hoc Tukey test or Bonferroni correction was used.

An exact one-tailed permutation test was implemented in MATLAB for the time-course data in [Figure 7](#fig7){ref-type="fig"}F. The statistic used was the sum across days of the difference between the mean infiltration in the Cre^-^ and Cre^+^ cohorts.

For all data, differences were considered significant whenever p \< 0.05. ^∗^ p \< 0.05; ^∗∗^ p \< 0.01; ^∗∗∗^ p \< 0.001; ^∗∗∗∗^ p \< 0.0001. Specific statistical parameters (e.g., number of animals used) can be found in the figure legends.

Data and Software Availability {#sec4.6}
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The accession number for the RNA-seq data reported in this paper is GEO: [GSE105159](ncbi-geo:GSE105159){#intref0025}.
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Document S1. Figures S1--S7Movie S1. Inefficient Angiogenesis in AML-Burdened Mice, Related to Figure 2Representative maximum projection of 3D time-lapse data (shown at 10 frames per second) of an area from a control (left) and leukemic (right) Flk1-GFP mouse collected every 90s for 90min (shown in Figure 2G). Red arrowheads point to vascular sprouts that rapidly retract. Black: Flk1-GFP+ cells. Representative of 4 control and 3 leukemic mice.Movie S2. Blood Vessel Fragmentation in Mice with AML, Related to Figure 2Maximum projection of 3D time-lapse data (shown at 10 frames per second) of vascular disintegration (circled area; red arrows) in a leukemic Flk1-GFP mouse. Filmed every 90s for 90min. Black: Flk1-GFP+ cells. Equivalent events were never observed in control mice.Movie S3. Circulating Endothelial Debris in BM Vessels of AML-Burdened Mice, Related to Figures 2 and S2Representative 2D time-lapse data collected every 156ms for 4min 24s (shown at 5 frames per second) from a Flk1-GFP mouse reconstituted with mTomato+ healthy hematopoietic cells (left; Control) and a Flk1-GFP mouse infiltrated with mTomato+ AML (right; AML). In control mice (left) no debris particles are detected in circulation but in leukemic mice (right) frequent endothelial debris is found inside the vascular lumen, sometimes adhering to the endothelium. Green: GFP signal; red: mTomato+ healthy hematopoietic cells (left) or AML cells (right); blue: Cy5-Dextran. Arrowheads follow some of the debris observed in circulation. Representative of 3 control and 4 leukemic mice.Movie S4. Stroma Dynamics in Mice with AML, Related to Figures 3 and S4Representative maximum projections of 3D time-lapse data (shown at 10 frames per second) collected at ten-minute intervals for 7h and 20min from a mT/mG control (left) chimera and a mT/mG chimera with high infiltration of GFP+YFP+ AML (right). AML cells not shown for clarity purposes. Red: mTomato+ stromal cells; blue: Cy-5 dextran+ blood vessels. Arrows follow oscillating vessels in AML-burdened mouse. Representative of 3 control and 3 leukemic mice.Movie S5. Cell Adhesion to the Splenic Endothelium, Related to Figure 5Representative maximum projections of time-lapse data (shown at 7 frames per second) of 2 areas scanned every 30s for 15min from the spleen of a leukemic Flk1-GFP mouse with mTomato+ residual healthy hematopoietic cells. In area 1, the arrow points to a healthy hematopoietic cell adhering statically to the endothelium. In position 2, a cell adheres, crawls, and detaches from the endothelium. Green: Flk1+ GFP ECs; red: mTomato+ healthy hematopoietic cells; blue: Cy5-Dextran.Movie S6. Transendothelial Migration in the BM, Related to Figure 5Representative maximum projections of time-lapse data (shown at 7 frames per second) of 2 areas scanned every 30s for 15min from the BM of a leukemic Flk1-GFP mouse with mTomato+ residual healthy hematopoietic cells. In position 1, the arrow points to a normal hematopoietic cell intravasating and leaving the BM. In position 2, a cell adheres and extravasates towards the tissue. Green: Flk1+ GFP ECs; red: mTomato+ non-malignant hematopoietic cells; blue: Cy5-Dextran.Movie S7. Turbulent Blood Flow in Vessels within AML Infiltrated BM, Related to Figure 5Representative maximum projection (shown at 7 frames per second) of a vascular bifurcation area collected every 30s for 15min from the spleen of a healthy (left) and a leukemic (right) Flk1-GFP mouse. Dark circles: AML cells form intravascular clusters that adhere to the endothelium and block blood flow; Green: Flk1+ GFP ECs; Red: mTomato+ non-malignant hematopoietic cells; Yellow: Cy5-Dextran.Document S2. Article plus Supplemental Information
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